{"schema_version":"1.0","type":"article","title":"肺癌免疫治療再加ADC：腫瘤更常縮小，為何三期仍未過關？","url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.md","lang":"zh-Hant","date":"2026-10-01","publish_at":"2026-10-01T08:00:00+08:00","updated_at":"2026-10-01","category":"醫學大會","topic":"醫學大會","tags":["Trodelvy","EVOKE-03","肺癌","TROP2 ADC","東亞次群","浩鼎"],"summary":"肺癌第一線加上ADC，腫瘤反應率提高卻未通過預設PFS門檻，毒性負擔也上升。EVOKE-03如何改變後續開發判斷，東亞訊號與浩鼎的TROP2產品又各需要什麼人體證據？","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"約620名符合未治療轉移性NSCLC、PD-L1 TPS≥50%及指定EGFR、ALK、ROS1致敏驅動變異陰性等研究條件的患者，分為SG加pembrolizumab與pembrolizumab單藥兩組，兩組共同指向PFS與OS主要終點。","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3/FIG01_ZH_v1.png"},{"alt":"圖面以四個平行區域呈現同一比較順序「SG＋pembrolizumab／pembrolizumab」：PFS區標示11.8／7.7個月、HR 0.81、P=0.0252且未達預設門檻；OS區標示期中OS 21.5／22.8個月；ORR區標示55.6%／43.7%；毒性區標示第3級以上TRAE 55.7%／16.5%。圖中沒有Kaplan-Meier生存曲線，也沒有把ORR或HR改寫成主要PFS成功。","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3/FIG02_ZH_v1.png"},{"alt":"左側畫面是620人整體主要分析與「PFS未過門檻」；右側較大的East Asia區域完整包含較小的China-only區域。圖面只直接呈現「East Asia：PFS較有利趨勢」與「China-only：OS post-hoc探索」，沒有森林圖、地區n、CI或interaction數字，且面積不代表樣本比例或效果大小。相鄰圖說補充：公開摘要同時指出East Asia與China-only患者分層的OS均屬post-hoc exploratory，而East Asia PFS次群的預設性仍未知。","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3/FIG03_ZH_v1.png"},{"alt":"中央TROP2陽性腫瘤細胞的膜上標記連向Trodelvy、OBI-992與OBI-902三種不同抽象ADC；強調各自人體資料與不可跨試驗排名。沒有相鄰供應鏈公司列或療效比較數字。","url":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3/FIG04_ZH_v3_20260927.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/trodelvy-evoke03-east-asia-subgroup-phase3/FIG01_ZH_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-01）。肺癌免疫治療再加ADC：腫瘤更常縮小，為何三期仍未過關？。https://drugnews.com.tw/articles/2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-10-01-trodelvy-evoke03-east-asia-subgroup-phase3-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}